Board of Directors
  • Leon Recanati - Chairman of the Board

    Leon Recanati has served on our board of directors since May 2005 and has served as Chairman since March 7, 2013. Mr. Recanati currently serves as a board member of Evogene Ltd., a plant genomics company listed on the TASE and New York Stock Exchange. He is also a board member of the following private companies: GlenRock Israel Ltd., GlenRock Medical, Shellcase, Gov, Govli Financial Services Ltd., Govli Limited, Microbes Inc., RelTech Holdings Ltd., Legov Ltd., Insight Capital Ltd., Shavit Capital Fund and Newbank Ltd. He is currently Chairman and Chief Executive Officer of GlenRock. Previously, Mr. Recanati was Chief Executive Officer and/or Chairman of IDB Holding Corporation; Clal Industries Ltd.; Azorim Investment Development and Construction Co Ltd.; Delek Israel Fuel Corporation; and Super-Sol Ltd. He also founded Clal Biotechnologies Industries Ltd., a biotechnology investment company operating in Israel. Mr. Recanati holds an MBA degree from the Hebrew University of Jerusalem and Honorary Doctorates from the Technion Institute of Technology and Tel Aviv University.

  • David Tsur - Deputy Chairman of the Board

    David Tsur is the Co-founder of Kamada and served has our Chief Executive Officer and on our board of directors since the company's inception in 1990 until July 2015.  Currently he serves as our Active Deputy Chairman of the Board. Prior to co-founding Kamada, Mr. Tsur was Chief Executive Officer of Arad Systems and RAD Chemicals Inc. He has also held various positions in the Israeli Ministry of Economy (formerly named the Ministry of Industry and Trade), including Chief Economist and Commercial Attaché in Argentina and Iran. Mr. Tsur holds a BA degree in Economics and International Relations and an MBA in Business Management from the Hebrew University of Jerusalem.


  • Saadia Ozeri

    Mr. Ozeri has servsed on our bourd of directors since May 2016. Mr. Ozeri has extensive experience across a broad range of industries and geographies in business strategy, management and financing. Mr. Ozeri served as the Company's CFO from 2004 to 2007 leading its IPO in the Tel-Aviv Stock Exchange. He is a certified public accountant in Israel and also holds a Bachelor of Business degree majoring in Accountancy, from the College of Management – Academic Studies.  Mr. Ozeri is currently the CEO of Kuf Dalet (104) Ltd., a private holding company engaged in investments in Tech, Real Estate and Infrastructure.  Mr. Ozeri is also the Chairman of the Board of Rotshtein Nadlan Ltd., a real estate public company traded in the Tel-Aviv Stock Exchange.  

  • Avraham Berger

    Mr. Avraham Berger has served on our board of directors since August 2016. Mr. Berger currently serves as technology investor.  Until 2014, Mr. Berger served as a senior partner and chief executive officer of PwC Israel, for more than 20 years.  Mr. Berger joined PwC Israel in 1976 and led it from 1991.  Mr. Berger has vast experience in mergers and acquisitions and complex public offerings, both in Israel and abroad.  Mr. Berger lectures at professional forums and has published several articles in the professional press.  Mr. Berger also serves as Chairman of the board of directors of TopAudio Ltd. and serves as director on the board of Weizmann Institute of Science.  Mr. Berger holds a Bachelor’s degree in Accounting and Economics awarded from Tel Aviv University and is a certified public accountant in Israel.


  • Gwen A. Melincoff

    Ms. Gwen A. Melincoff has over 25 years of leadership experience in the biotechnology and pharmaceutical industries. Her experience has spanned public and private company boards, venture financing, business development, licensing, mergers and acquisitions, research operations, marketing, product management and project management.
    Ms. Melincoff is an advisor to Phase 1 Ventures and Verge Genomics. From August 2014 to September 2016, she served as Vice President of Business Development at BTG International Inc. a UK- specialist healthcare company.
    From September 2004 to  December 2013, Ms. Melincoff was Senior Vice President of Business Development at Shire Pharmaceuticals. Additionally, from 2010 to 2013 she led the Strategic Investment Group (SIG). Ms. Melincoff served as a board member/board observer at Tobira Therapeutics (acquired by Allergan), DBV Technologies, AM Pharma, ArmaGen Technologies, Promethera Biosciencs, Naurex Inc. (acquired by Allergan) and Enterome. Ms. Melincoff was named a “Top Women in Biotech 2013” by Fierce Biotech as well as being named to the Powerlist 100 of Corporate Venture Capital in 2012 and 2013.
    Prior to joining Shire, Ms. Melincoff held managerial and business development position at various pharmaceutical companies such as Adolor Corporation.
    Ms. Melincoff has a B.S in Biology, a Master’s of Science in Management, and has attained the designation of the Certified Licensing Professional (CLP™).

  • Dr. Michael Berelowitz

    Dr. Michael Berelowitz has served on our Board of Directors since July 2015. Dr. Berelowitz currently serves as a biopharmaceuticals consultant, and is a member of several Boards of Directors or Scientific Advisory Boards, including, Oramed Pharmaceuticals (NASDAQ: ORMP), Recro Pharma, Inc. (NASDAQ: REPH) and DIR Technologies. Dr. Berelowitz has more than 40 years' experience in clinical development and academic research, including 15 years of experience in pharmaceutical development with Pfizer, Inc. where he served as a Senior Vice President and Head of Clinical Development and Medical Affairs in the Specialty Care Business Unit. Prior to that, Dr. Berelowitz spent a number of years in academia and has held several appointments at the University of Chicago, University of Cincinnati College of Medicine, SUNY at StonyBrook and, most recently, Mount Sinai School of Medicine. In Addition, Dr. Berelowitz has served on the Board of Directors of the American Diabetes Association, the Endocrine Fellows Foundation, the Clinical Initiatives Committee of the Endocrine Society and has chaired the Task Force on Research of the New York State Council on Diabetes.

    Dr. Berelowitz completed his medical degree, residency training in Pathology, Nuclear Medicine and Internal Medicine and fellowship training in Endocrinology and Metabolism at the University of Cape Town.


  • Jonathan Hahn

    Jonathan Hahn has served on our board of directors since March 2010. He is currently the President and a director of Tuteur. Previously, Mr. Hahn held a business development position in Forest Laboratories, Inc., based in New York. Mr. Hahn holds a BA degree from San Andrés University and an MBA degree from New York University — Stern School of Business, with specializations in Finance and Entrepreneurship.

  • Abraham Havron, Ph.D.

    Dr. Abraham Havron has served on our board of directors since March 2011 and is an external director within the meaning of the Companies Law. Since 2005 and until its acquisition by OPKO Health Inc. in 2013, Dr. Havron served as the Chief Executive Officer and a director of PROLOR Biotech Inc. Dr. Havron is a 34-year veteran of the biotechnology industry and was a member of the founding team and Director of Research and Development of Interpharm Laboratories Ltd. (a subsidiary of Merck Serono S.A.) from 1980 to 1987. Dr. Havron served as Vice-President Manufacturing and Process-Development of BioTechnology General Ltd., based in Rehovot, Israel (now, a subsidiary of Ferring Pharmaceuticals) from 1987 to 1999; and Vice President and Chief Technology Officer of Clal Biotechnology Industries Ltd. from 1999 to 2003. Dr. Havron earned his PhD in Bio-Organic Chemistry from the Weizmann Institute of Science, and served as a Research Fellow at the Harvard Medical School, Department of Radiology.

Senior Management
  • Amir London - CEO

    Amir London assumed responsibility as Kamada's CEO in July 2015.
    Prior to that, he has served as our Senior Vice President, Business Development. Mr. London brings with him over 20 years of senior management and international business development experience.

    Prior to joining Kamada , Mr. London was the COO of Fidelis Diagnostics, a US-based provider of innovative in-office medical diagnostic services. Earlier in his career Mr. London was the CEO of Promedico, a leading Israeli-based $350 million healthcare distribution company, and the General Manager of Cure Medical, providing contract manufacturing services for clinical studies, as well as home-care solutions. Before that, for 10 years, Mr. London was a Partner with Tefen, an international publicly-traded operations management consulting firm, responsible for the firm's global biopharma practice. Mr. London holds a B.Sc. in Industrial and Management Engineering from the Technion in Haifa, Israel.

  • Gil Efron - Deputy CEO & CFO

    Gil Efron is serving as our Chief Financial Officer since September 2011 and also assumed responsibility as Deputy CEO in July 2015. He has over 20 years of experience in various finance management positions.

    Mr. Efron is also currently the owner and Chief Executive Officer of GEO Consulting Ltd. which he founded in February 2011 and provides financial management services. From February 2006 until 2011, Mr. Efron served as Chief Financial Officer of RRsat Global Communications Ltd. (Nasdaq: RRST), a provider of distribution and content management services for television and radio broadcasting networks. Prior to that, he served in various finance positions, including as Chief Financial Officer of Proficiency Ltd., as Chief Financial Officer of IP Planet Network Ltd. and as a senior auditor with the Israeli member firm of PricewaterhouseCoopers. Mr. Efron also served as a director of Poalim Ventures I Ltd. Mr. Efron is a certified public accountant in Israel and holds a BA degree in Economics and Accounting and an MA degree in Business Administration from the Hebrew University of Jerusalem.

  • Liliana Bar, PhD - VP Research and Development

    Dr. Liliana Bar has served as our Vice President, Research and Development since June 2012. Prior to joining us, she was Director of the Development and Base Business Unit and Manager of the Development and Base Unit of Omrix from 2007. Dr. Bar holds a MSc degree and PhD in Applied Chemistry from the Hebrew University of Jerusalem and was a Research Associate at the Biochemistry Department at Hadassah Medical School at the Hebrew University of Jerusalem and a Research Associate at the Biochemistry Department of University of Virginia.

  • Eran Nir - VP Operations

    Eran Nir serves as our VP Operations since November 2016. Mr. Nir has over 14 years of operation management experience in the pharmaceutical and medical industries. His recent roles include management of TEVA's Pharmaceutical plant in Jerusalem, VP Operations of Emilia Cosmetics and management of a medical equipment plant of Philips Medical Systems. Mr. Nir’s extensive experience spans across the management of large scale FDA and EMA- approved manufacturing facilities, tech-transfer of new products from development to production and the implementation of world-class operational excellence systems.

    Mr. Nir has B.SC degree in Industrial Engineering and M.B.A. both from Ben Gurion University.

  • Yael Brenner - VP Quality

    Yael Brenner has served as our Vice President Quality since March 2015. Mrs. Yael Brenner has experience of more than 20 years in Quality Management, including QA and QC managerial positions in the pharmaceutical industry. Prior to her joining Kamada, her last position in Teva Pharmaceuticals Industries was Senior Director Quality Operations of Teva Kfar Saba Site, managing over 400 workers in QA, QC and RA. Mrs. Brenner holds B.Sc. and M.Sc. degrees in Chemistry from the Technion, Haifa, and in addition Certified Quality Engineer (CQE) from the American and the Israeli and Societies for Quality.

  • Shani Dotan - VP Human Resources

    Shani Dotan has served as our Vice President, Human Resources since Nov 2013.
    Mrs. Dotan has more than a decade of expertise in local and global organizations and in all HR aspects.
    Prior to joining us, she served as the Human Resources Manager at Teva Pharmaceuticals at the Plant in Jerusalem.
    Mrs. Dotan holds an MA degree in Psychology and a BA degree in Behavioral Science, both from Ben-Gurion University

  • Orit Pinchuk - VP, Regulatory Affairs

    Orit Pinchuk has served as our Vice President, Regulatory Affairs since October, 2014. Mrs. Pinchuk has experience of more than 20 years in the pharmaceutical industry, fulfilling key positions that cover, among others, disciplines of Regulatory Affairs and Compliance. Prior to her joining Kamada, her last positions in Teva Pharmaceuticals Industries were Director of Compliance and RA, Operation IL and Sr. Director RA, R&D and Operation IL. She has extensive experience with FDA, EMA and CANADA Health Authorities.
    Mrs. Pinchuk holds B.Tech. in Textile Chemistry from Shenkar College for Engineering and Design and M.Sc. in Applied Chemistry from Jerusalem Hebrew University.

  • Naveh Tov, M.D., Ph.D. - VP, Clinical Development and Medical Director for Pulmonary Diseases

    Dr. Tov served in both active hospital academic and clinical positions at Bnai Zion Medical Center, Haifa, Israel.  He specializes in Internal, Pulmonary and Sleep Medicine and served as Head of the Pulmonary Unit, and as Deputy of Internal Ward C, at Bnei Zion Medical Center, for 14 years.  During these years, Dr. Tov served in academia and held appointments at the Bruce Rappoport School of Medicine-Technion in Haifa, Israel. 

    Dr. Tov is a member of the American Thoracic Society and the European Respiratory Society. He holds an M.D. and a Ph.D. from the Bruce Rappoport School of Medicine-Technion.

  • Ruth Wolfson, PhD - Senior VP, Scientific Affairs

    Dr. Ruth Wolfson has served as our Senior Vice President, Quality and Regulatory Affairs since 2004. She has more than 15 years of experience in regulatory affairs, including submissions to the FDA, EMA and the Health Protection Branch in Canada.

    From 1989 to 2004, she served as Head of Regulatory Affairs at InterPharm Laboratories Ltd., a biopharmaceutical corporation.

    Ms. Wolfson holds a BSc degree in Agriculture and an MSc degree in Biochemical Agriculture, both with distinction, from the Hebrew University of Jerusalem, as well as a PhD from the Weizmann Institute’s Department of Biochemistry.